Magic bullets to kill nasty osteoclasts

Endocrinology

Volumn 146, Issue 8, 2005, Pages 3233-3234

  Khosla, Sundeep ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; OSTEOPROTEGERIN FC FRAGMENT; PAMIDRONIC ACID; PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

CELL ACTIVITY; CELL SURFACE; CLINICAL TRIAL; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; METABOLIC BONE DISEASE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; CARRIER PROTEINS; CELL DEATH; GLYCOPROTEINS; HYPERCALCEMIA; MEMBRANE GLYCOPROTEINS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 23044480036     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2005-0549     Document Type: Short Survey

References (15)

1. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ 2005 The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146:3235-3243
2. Albright F 1941 Case records of the Massachusetts General Hospital: case 39061. N Engl J Med 225:789-796
3. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE 1980 Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 303:1377-1383
4. Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, Hudson PJ, Martin TJ, Wood WI 1987 A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893-896
5. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Milstone LM, Barton DE 1988 Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 85:597-601
6. Juppner H, Abou-Samra A-B, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF, Hock J, Potts JT, Kronenberg HM, Segre GV 1991 A G protein-linked receptor for parathyroid hormone and parathyroid hormonerelated peptide. Science 254:1024-1026
7. Suda T, Takahashi N, Martin TJ 1992 Modulation of osteoclast differentiation. Endocr Rev 13:66-80
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
9. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ 1991 Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73:1309-1315
10. Lee S-K, Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561
11. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ 2000 In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871
12. Locklin RM, Khosla S, Turner RT, Riggs BL 2003 Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89:180-190
13. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H-L, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia X-Z, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545
14. Lacey DL, Timms E, Tan H-L, Dunstan CR, Burgess T, Elliott R, Colombero A, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, SArosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
15. McClung MR, Lewiecki EM, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman S, Chesnut CH, Murphy R, Holloway DL, Bekker PJ 2004 AMG 162 increases bone mineral density (BMD) within 1 month in postmenopausal women with low BMD. J Bone Miner Res 19(Suppl 1):S20